|1.||Bagnato, Anna: 34 articles (11/2014 - 03/2002)|
|2.||Rosanò, Laura: 32 articles (11/2014 - 03/2002)|
|3.||Spinella, Francesca: 30 articles (11/2014 - 03/2002)|
|4.||Di Castro, Valeriana: 27 articles (11/2014 - 03/2002)|
|5.||Matsumura, Yasuo: 24 articles (09/2013 - 08/2002)|
|6.||Yanagisawa, Masashi: 22 articles (09/2014 - 08/2002)|
|7.||Natali, Pier Giorgio: 22 articles (04/2014 - 08/2002)|
|8.||Miyauchi, Takashi: 20 articles (11/2014 - 08/2002)|
|9.||Schiffrin, Ernesto L: 19 articles (04/2014 - 02/2002)|
|10.||Barton, Matthias: 17 articles (11/2014 - 02/2002)|
|1.||Pulmonary Hypertension (Ayerza Syndrome)
01/01/1995 - "Endothelin-1 (ET-1) is believed to have a role in the pathogenesis of pulmonary hypertension, and ET antagonists may therefore be useful in the treatment of the disease. "
04/01/1998 - "Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension."
03/15/1991 - "Patient with pulmonary hypertension have substantial alterations in plasma immunoreactive endothelin-1, which may reflect changes in net release or clearance of endothelin-1 by the lung. "
06/01/2013 - "Based on these studies, drugs that increase NO bioavailability, attenuate endothelin-1 induced pulmonary vasoconstriction, or prevent exaggerated sympathetic activation have been shown to be useful for the treatment/prevention of exaggerated pulmonary hypertension during acute short-term high altitude exposure. "
06/01/2001 - "Endothelin-1 plasma concentration increases in the early phase of pulmonary hypertension development during respiratory distress syndrome: a study in newborn lambs."
01/01/2001 - "Experimental studies suggest that endothelin-1 antagonists are effective in lowering blood pressure in hypertensives, and also exert beneficial clinical and haemodynamic effects in patients with congestive heart failure. "
07/01/2000 - "Big endothelin-1 (2.6+/-0.4 vs. 1. 7+/-0.1 pM; P=0.04) and C-terminal fragment immunoreactivity (2. 1+/-0.3 vs. 0.6+/-0.1 pM; P<0.0001) were each significantly greater in heart failure patients than controls. "
03/01/2001 - "Although reduced pulmonary clearance of endothelin-1 (ET-1) has been suggested to contribute to increased circulating levels in congestive heart failure (CHF), the regulation of the pulmonary ET system with CHF remains to be defined. "
12/21/1999 - "Pulmonary clearance of endothelin-1 on heart failure: reduced or normal?"
07/04/2009 - "Several studies have analyzed big endothelin-1 as a marker of mortality in patients with severe heart failure (HF). "
|3.||Hypertension (High Blood Pressure)
06/01/1993 - "In patients with CHF, big endothelin-1 was, independent of hypertension history, significantly greater than in hypertensive patients with normal cardiac function and in control subjects (both p < 0.0001). "
09/01/2013 - "The aim of the present study was to determine the changes in cardiac makers and endothelin-1 (ET-1) in marathoners with exercise induced hypertension compared to normotensive controls before and after running a marathon. "
02/01/2010 - "The purpose of this study was to determine the role of endothelin 1 in mediating sFlt-1-induced hypertension in pregnant rats. "
01/01/2010 - "The current study sought to evaluate whether dysfunction of the vasoactive endothelin-1 (ET-1) system is involved in the pathogenesis of hypertension-induced retinopathy in an animal model of systemic hypertension. "
11/01/2008 - "The purpose of this study was to investigate the role of endothelin-1 Lys198Asn polymorphism in patients with severe arterial hypertension as well as associated endorgan damages. "
|4.||Cardiomegaly (Heart Hypertrophy)
04/01/1996 - "These data suggest that blocking the action of endothelin-1 with a receptor antagonist ameliorates cardiac hypertrophy in this model system, and that this action is not mediated by ameliorating hemodynamic changes."
05/01/2015 - "Going the distance: Epigenetic regulation of endothelial endothelin-1 controls cardiac hypertrophy."
05/01/2015 - "Our data suggest that SET1 epigenetically activates endothelin-1 transcription in endothelial cells, thereby contributing to Ang II-induced cardiac hypertrophy. "
02/13/2015 - "During high-salt intake, the sik1(+/+) mice exhibited an increase in SIK1 expression in the VSMCs layer of the aorta, whereas the sik1(-/-) mice exhibited upregulated transforming growth factor-β1 signaling and increased expression of endothelin-1 and genes involved in VSMC contraction, higher systolic blood pressure, and signs of cardiac hypertrophy. "
01/14/2011 - "ZFP260 is an inducer of cardiac hypertrophy and a nuclear mediator of endothelin-1 signaling."
07/01/2010 - "Hepatic stellate cell activation and increased endothelin-1 production play a crucial role in hepatic ischemia/reperfusion injury in cholestatic liver."
05/01/2010 - "Endothelin-1 (ET-1) is a potent endothelium-derived vasoconstrictor that might aggravate reperfusion injury. "
11/01/2004 - "Endothelin-1 has been shown to aggravate the ischemic-reperfusion injury in the neocortex of rats. "
09/01/2004 - "Endothelin-1 (ET-1) is a potent vasoconstrictor, which has been implicated in ischemic conditions and ischemia-reperfusion injury. "
08/01/2002 - "Endothelin-1 (ET-1) is believed to play an important role in cardiac ischaemia/reperfusion injury. "
|1.||Nitric Oxide (Nitrogen Monoxide)
|2.||Endothelin Receptors (Endothelin Receptor)
|4.||Endothelin-1 (Endothelin 1)
|5.||Interleukin-6 (Interleukin 6)
|6.||Biological Markers (Surrogate Marker)
|7.||Idiopathic pulmonary hypertension
|9.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|10.||Messenger RNA (mRNA)
|2.||Continuous Positive Airway Pressure
|4.||Cardiopulmonary Resuscitation (CPR)